Syndax Pharmaceuticals Inc (SNDX): debt financing — Syndax issues $250M of 2.25% convertible notes due 2031, net proceeds ~$243M

Syndax Pharmaceuticals Inc

Issued $250M aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in private placement.
Net proceeds of approximately $243M after placement agent fees and expenses.
Proceeds to be used for general corporate purposes including R&D, commercialization, and business development.
Initial maximum conversion of 13,631,400 shares of common stock (conversion rate 54.5256 shares per $1,000).
Notes and conversion shares unregistered; issued under Section 4(a)(2) exemption.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Syndax Pharmaceuticals Inc incurred convertible notes of $250.0 million aggregate principal amount with U.S. Bank Trust Company, National Association at 2.25% maturing due 2031.

Instrument: convertible notes
Principal: $250.0 million aggregate principal amount
Counterparty: U.S. Bank Trust Company, National Association
Rate: 2.25%
Maturity: due 2031
Event: incurrence

Exact text from the filing

issued $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Syndax Pharmaceuticals Inc issued $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 of convertible note to certain investors for approximately $243.0 million net proceeds.

Security: convertible note
Shares: $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
Purchaser: certain investors
Consideration: approximately $243.0 million net proceeds

Exact text from the filing

(and the foregoing description is qualified in its entirety by reference to such documents). Proceeds The Company’s net proceeds from the Private Placement were approximately $243.0 million, after deducting the placement agent’s fees and Private Placement expenses payable by the Company. The Company expects to use the net proceeds from the Private Placement for

View on SEC.gov

295 debt financings filed in the last 30 days. Browse all debt financings →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001193125-26-266027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.